

Patient ID SA00175529	Patient Name TESTING, BALFP_ABNORMAL	Birth Date 2002-02-02	Sex M	Age 23
Order Number SA00175529	Client Order Number SA00175529	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 May 2025 14:57		

Pediatric B-ALL/LBL panel, FISH

Result Summary

Abnormal

Interpretation

The result is abnormal and indicates 90% of nuclei had ETV6::RUNX1 fusion.

ETV6::RUNX1 fusion is associated with a favorable prognosis in B-lymphoblastic leukemia/lymphoma (B-ALL) (Iacobucci et al., J Clin Oncol 35:975–983, 2017; Roberts et al., Nat Rev Clin Onc 12:344–357, 2015).

Clinical and pathologic correlation is recommended.

For monitoring response to therapy, FISH for ETV6::RUNX1 fusion is available, test BALMF [ALL (B-cell), Specified FISH].

Result Table

Abnormality Name	Result	Ab	n% Cutoff%
Xp22.33/ Yp11.32(3'CRLF2retention,5 'loss)	Normal		<10.0
t(9;22) BCR::ABL1 fusion	Normal		<4.0
t(1;19) TCF3::PBX1 fusion	Normal		<4.0
der(19)t(1;19) TCF3::PBX1 fusion	Normal		<4.0
+4CEN(D4Z1x3)	Normal		<20.0
+10CEN(D10Z1x3)	Normal		<7.0
+17CEN(D17Z1x3)	Normal		<7.0
t(12;21) ETV6::RUNX1 fusion	Abnormal	90	<4.0
+21q22(RUNX1x3)	Normal		<7.0
14q32(IGH sep)	Normal		<15.0
8q24.21(MYC sep)	Normal		<10.0
t(8;14) IGH::MYC fusion	Normal		<4.0
11q23(KMT2A sep)	Normal		<10.0

Result

nuc ish (ETV6,RUNX1)x3(ETV6 con RUNX1)x2[180/200]

Reason for Referral

r/o B-cell ALL

Specimen

Bone Marrow

Source

Left iliac crest

Method

Locus and probes	[Strategy;#Nuclei;Vendor]
Xp22.33/Yp11.32(3'CRLF2,5'CRLF2)	[BAP;100;C]
1q23(PBX1), 19p13.3(TCF3)	[DFISH;200;LDT]
4CEN(D4Z1), 10CEN(D10Z1), 17CEN(D17Z1)	[COPY#;100;AM]
8CEN(D8Z2), 8q24.21(MYC), 14q32(IGH)	[DFISH;200;AM]
8q24.21(5'MYC,3'MYC)	[BAP;100;AM]
9q34(ABL1), 22q11.2(BCR)	[DFISH;200;AM]
11q23(5'KMT2A,3'KMT2A)	[BAP;100;AM]
12p13(ETV6), 21q22(RUNX1)	[DFISH;200;LDT]
14q32(3'IGH,5'IGH)	[BAP;100;LDT]

Probe strategies include:
DFISH=dual color, double fusion;
BAP=break-apart probe;
COPY#=region gain and loss.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AM = Abbott Molecular, Inc (Des Plaines, IL)
C = Cytocell, Inc. (Cambridge, UK)

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292



Patient ID SA00175529	Patient Name TESTING, BALFP_ABNORMAL	Birth Date 2002-02-02	Sex M	Age 23
Order Number SA00175529	Client Order Number SA00175529	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 May 2025 14:57		

Updated Gene Symbols
KMT2A: previously reported as MLL

Disclaimer
Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Released By
Xinjie Xu, Ph.D.

Received: 13 May 2025 10:49

Reported: 21 May 2025 14:11

MCR

MCR

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292